Treating Thalassemia Patients with Luspatercept: An Expert Opinion Based on Current Evidence
Origa R.Last
2023-01-01
Abstract
Luspatercept has recently been approved for the treatment of beta-thalassemia and its use in clinical practice has been increasing. As it is the first erythroid maturation drug available for this diagnosis, the expertise about its use is still limited. To address this point, and to promote awareness and guide the clinical use of luspatercept in beta-thalassemia, this paper was developed as a consensus by experts from the Italian Society of Thalassemia and Hemoglobinopathies (SITE). After a brief presentation of the core features of luspatercept, a comprehensive set of questions is addressed, covering relevant aspects for the practical management of this new therapeutic option.File | Size | Format | |
---|---|---|---|
Treating Thalassemia Patients with Luspatercept.pdf open access
Type: versione editoriale
Size 242.43 kB
Format Adobe PDF
|
242.43 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.